(Q34503560)

2 August 2017

1 reference

title

Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery (English)

1 reference

2 August 2017

1 reference

James T Dalton

3

0 references

author name string

Scott Segal

series ordinal

1

1 reference

PubMed ID

16548787

2 August 2017

Ramesh Narayanan

series ordinal

2

1 reference

PubMed ID

16548787

2 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

15

1 reference

2 August 2017

4

1 reference

2 August 2017

377-387

1 reference

Molecular mechanisms of action of steroid/thyroid receptor superfamily members

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Discovery of nonsteroidal androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

CP8668, a novel orally active nonsteroidal progesterone receptor modulator with tetrahydrobenzindolone skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Non-steroidal steroid receptor modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Orphan nuclear receptors--new ligands and new possibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

The rat androgen receptor: primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Domains of the Human Androgen Receptor Involved in Steroid Binding, Transcriptional Activation, and Subcellular Localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Molecular pathways of steroid receptor action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Motoneuronal cell death is not correlated with aggregate formation of androgen receptors containing an elongated polyglutamine tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Hyperthermia-induced proteasome inhibition and loss of androgen receptor expression in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Expression and function of androgen receptor coactivators in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Selective modulation of genomic and nongenomic androgen responses by androgen receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Androgen receptor functions from reverse genetic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Suppressive function of androgen receptor in bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Testosterone metabolism, dose-response relationships and receptor polymorphisms: selected pharmacological/toxicological considerations on benefits versus risks of testosterone therapy in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Testosterone replacement therapy and the risk of prostate cancer: a perspective view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Hormone treatment of the adult transsexual patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

A selective androgen receptor modulator for hormonal male contraception

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Pharmacodynamics of selective androgen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Male hypogonadism : an update on diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Prostate cancer in men using testosterone supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Metabolic management of patients with severe burns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Post burn muscle wasting and the effects of treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Impact of prescription coverage on hospital and physician costs: a case study of medicare beneficiaries with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Catabolic/anabolic balance and muscle wasting in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Effect of testosterone replacement on trabecular architecture in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Parathyroid hormone as a therapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

9 clinical cases of nonhealing pressure ulcers in patients with spinal cord injury treated with an anabolic agent: a therapeutic trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Is seborrhea a sign of autonomic impairment in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

Antiandrogenic steroidal sulfonylpyrazoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.4.377

10.1517/13543784.15.4.377

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

16548787